ArticleFrontiers in oncology2025
Prediction of solid pseudopapillary tumor invasiveness of the pancreas based on multiphase contrast-enhanced CT radiomics nomogram.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To construct a multiphase contrast-enhanced CT-based radiomics nomogram that combines traditional CT features and radiomics signature for predicting the invasiveness of pancreatic solid pseudopapillary neoplasm (PSPN). Methods: A total of 114 patients with surgical pathologic diagnoses of PSPN were retrospectively included and classified into training (n = 79) and validation sets (n = 35). Univariate and multivariate analyses were adopted for screening traditional CT features significantly associated with the invasiveness of PSPN as independent predictors, and a traditional CT model was established. Radiomics features were extracted from the contrast-enhanced CT images, and logistic regression analysis was employed to establish a machine learning model, including an unenhanced model (model U), an arterial phase model (model A), a venous phase model (model V), and a combined radiomics model (model U+A+V). A radiomics nomogram was subsequently constructed and visualized by combining traditional CT independent predictors and radiomics signature. Model performance was assessed through Delong's test and receiver operating characteristic (ROC) curve analysis. Decision curve analysis (DCA) was applied to assess the model's clinical utility. Results: Multivariate analysis suggested that solid tumors (OR = 6.565, 95% CI: 1.238-34.816, P = 0.027) and ill-defined tumor margins (OR = 2.442, 95% CI: 1.038-5.741, P = 0.041) were independent predictors of the invasiveness of PSPN. The areas under the curve (AUCs) of the traditional CT model in the training and validation sets were 0.653 and 0.797, respectively. Among the four radiomics models, the model U+A+V exhibited the best diagnostic performance, with AUCs of 0.857 and 0.839 in the training and validation sets, respectively. In addition, the AUCs of the nomogram in the training and validation sets were 0.87 and 0.867, respectively, which were better than those of the radiomics model and the traditional CT model. The DCA results indicated that with the threshold probability being within the relevant range, the radiomics nomogram offered an increased net benefit to clinical decision making. Conclusion: Multiphase contrast-enhanced CT radiomics can noninvasively predict the invasiveness of PSPN. In addition, the radiomics nomogram combining radiomics signature and traditional CT signs can further improve classification ability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.